President Donald Trump and Democrats in Congress agree on almost nothing, except for doing something about prescription drug prices, and the political pressure and a broader public backlash against price increases have already rattled the pharmaceutical industry, Avi Salzman writes in this week’s edition of Barron’s. House Democrats have cited 19 drugs in their scrutiny of the industry, drugs commercialized by AbbVie (ABBV), Amgen (AMGN), AstraZeneca (AZN), Celgen (CELG), Eli Lilly (LLY), Johnson & Johnson (JNJ), Mallinckrodt (MNK), Novartis (NVS), Novo Nordisk (NVO), Pfizer (PFE), Sanofi (SNY), and Teva Pharmaceutical (TEVA), the report notes. Further, the gross list price growth for the top six companies in U.S. prescription drug sales – Roche (RHHBY), Pfizer, AbbVie, J&J, Amgen and Merck (MRK) – has fallen sharply in recent years, the publication adds.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.